Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) remains a major cause of morbidity and mortality worldwide, and despite extensive research, only a few drugs are available for management of the disease. One strategy has been to up-regulate cholinergic neurotransmission to improve cognitive function, but this approach has dose-limiting adverse effects. To avoid these adverse effects, new drugs that target specific receptor subtypes of the cholinergic system are needed, and the M1 subtype of muscarinic acetylcholine receptor (M1-mAChR) has been shown to be a good target for this approach. By using several strategies, M1-mAChR ligands have been developed and trialled in preclinical animal models and in human studies, with varying degrees of success. This article reviews the different approaches to targeting the M1-mAChR in AD and discusses the advantages and limitations of these strategies. The factors to consider in targeting the M1-mAChR in AD are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M1-mAChR positive allosteric modulators (M1-PAMs), such as BQCA (53) and PF06764427 (54), achieve subtype selectivity through allosteric effects but have significant agonistic activity that may lead to side effects like diarrhea.544,553”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [544]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Allosteric modulators typically attach to regions distinct from the orthosteric site of receptors, inducing conformational changes to regulate the affinity and/or efficacy of orthosteric ligands, or to directly modulate receptor activity with positive, negative, or neutral effects.542–545”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [544]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
Hulme, E. C., Birdsall, N. J. M., & Buckley, N. J. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.003221 · Cited by 1,338
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Brannan S.K., Miller A.C., Paul S.M. and Breier A. (2018) KarXT, a combination of the M1/M4 cholinergic receptor agonist xanomeline and trospium for the treatment of psychosis and cognitive impairment in schizophrenia: phase I studies. Presented at Poster Session I of the American College of Neuropsychopharmacology 57th Annual Meeting, Hollywood, FL, U.S.A., Available from: https://acnp.societyconference.com/user/server/submission_pdf.php
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
Tacrine-Based Hybrids: Past, Present, and Future
Bubley, A., Erofeev, A. S., Gorelkin, P. V., Beloglazkina, E. K., Majouga, A. G., & Krasnovskaya, O. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021717 · Cited by 53
Khedraoui, M., Abchır, O., Nour, H., Yamari, I., Errougui, A., Samadi, A., & Chtita, S. (2024) · Pharmaceuticals · doi:10.3390/ph17070830 · Cited by 60
Uwada, J., Nakazawa, H., Muramatsu, I., Masuoka, T., & Yazawa, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076508 · Cited by 48
Yohn, S. E., Harvey, P. D., Brannan, S. K., & Horan, W. P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1421554 · Cited by 40
Wiesman, A. I., Gallego-Rudolf, J., Villeneuve, S., Baillet, S., & Wilson, T. W. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14110 · Cited by 25
Vaidya, S. P., Guerin, A. A., Walker, L. C., & Lawrence, A. J. (2022) · CNS Drugs · doi:10.1007/s40263-022-00964-8 · Cited by 28
AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist
Brahma, R., Moon, S., Shin, J.-M., & Cho, K. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-024-00945-7 · Cited by 22
Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography
Zhang, J., Fu, H., Lin, R., Zhou, J., Haider, A., Fang, W., Elghazawy, N. H., Rong, J., Chen, J., Li, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00573 · Cited by 20
Crosstalk between Adult Hippocampal Neurogenesis and Its Role in Alzheimer’s Disease
Tiwari, V., Mishra, A., Singh, S., & Shukla, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00119 · Cited by 19
G-protein coupled receptors in neuroinflammation, neuropharmacology, and therapeutics
Singh, A. P., Shadangi, S., & Rana, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117301 · Cited by 18
Tsimpili, H., & Zoidis, G. (2025) · Pharmaceuticals · doi:10.3390/ph18030369 · Cited by 20
Saito, A., Alvi, S., Valant, C., Christopoulos, A., Carbone, S., & Poole, D. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16023 · Cited by 14
Szczurowska, E., Szánti‐Pintér, E., Chetverikov, N., Randáková, A., Kudová, E., & Jakubík, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010507 · Cited by 18
Karmakar, V., & Gorain, B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103850 · Cited by 14
Knezović, A., & Šalković‐Petrišić, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02887-2 · Cited by 15
Muscarinic Receptors and Alzheimer’s Disease: New Perspectives and Mechanisms
Monaco, M., Trebesova, H., & Grilli, M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070407 · Cited by 16
Abdelfatah, S., Knorz, C., Ayoobi, A., Omer, E. A., Rosellini, M., Riedl, M., Meesters, C., & Efferth, T. (2024) · Pharmaceuticals · doi:10.3390/ph17010080 · Cited by 14
Tanaka, T., Katayama, T., & Imai, T. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109419 · Cited by 13
Al-Jaf, S., Soliman, A. Y., EL‐Yazbi, A. F., & Abd‐Elrahman, K. S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00614 · Cited by 8
Tang, R., Franz, C. E., Hauger, R. L., Dale, A. M., Dorros, S. M., Eyler, L. T., Fennema‐Notestine, C., Hagler, D. J., Lyons, M. J., Panizzon, M. S., et al. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.05.012 · Cited by 9
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions
Mohapatra, T. K., Nayak, R. R., Ganeshpurkar, A., Tiwari, P. K., & Kumar, D. (2025) · Ibrain · doi:10.1002/ibra.12197 · Cited by 9
Contreras, A., Jiménez‐Herrera, R., Djebari, S., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00697-5 · Cited by 7
Hamdan, M. F., Ramadhani, N. N., Aziz, A. Y. R., Sahra, M., Agrabudi, A. I., & Permana, A. D. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137589 · Cited by 9
Abraham, M. N., Nedeljkovic-Kurepa, A., Fernandes, T., Yaipen, O., Brewer, M. R., Leisman, D. E., Taylor, M. D., & Deutschman, C. S. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00787-x · Cited by 7
Emerging roles of immune cell-derived neurotransmitters in immunity and disease
Ng, L., Xiao, F., Deng, C., & Lu, L. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00028-2 · Cited by 6
Taheri, M., Mehr, M. A., & Ghafouri, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-80102-0 · Cited by 5
Dong, H., Weiss, K., Baugh, K., Meadows, M. J., Niswender, C. M., & Neul, J. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00384 · Cited by 4
Biswas, P., Rahman, M. H., Tabassum, A., Shoyshob, T. Z., Jalouli, M., Tareq, M. M. I., Imtiaz, M., Dona, H. A., Harrath, A. H., & Rahman, M. A. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/8847508 · Cited by 3
Acetylcholine - Recent Advances and New Perspectives
Heinbockel, T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106304 · Cited by 5
Lluna‐Galán, C., Izquierdo‐Aranda, L., de la Iglesia-Gómez, P., Béchet, C., Vidal-Puyuelo, P., Arango‐Daza, J. C., Adam, R., & Cabrero‐Antonino, J. R. (2025) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.5c05996 · Cited by 3
SUGIYAMA, N., Yamada, S., NAKAMURA, Y., MORITA, K., KANO, K., ISHIDA, K., Takeuchi, K., Kita, J., Sahara, S., SUGAWARA, K., et al. (2024) · Anticancer Research · doi:10.21873/anticanres.17395 · Cited by 3
CNS muscarinic receptors and muscarinic receptor agonists in Alzheimer disease treatment
Fisher, A., & Levey, A. I. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19088-9.00016-0 · Cited by 6
Computer-aided Drug Design for Alzheimer's Disease: Recent Advancements and Future Perspectives
Rohilla, S., & Goyal, G. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266343814250713100224 · Cited by 2
Fecik, M. J., & Savage, L. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110462 · Cited by 4
Wiesman, A. I., Gallego-Rudolf, J., Villeneuve, S., Baillet, S., & Wilson, T. W. (2024) · medRxiv · doi:10.1101/2024.04.13.24305551 · Cited by 2
Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease
Sunderman, C. L., Forero, K. V., Alorjani, Q., Buqaileh, R., Gallagher, G. M., Ventresca, S. M., Messer, W. S., & AbouAlaiwi, W. A. (2025) · Brain Sciences · doi:10.3390/brainsci15091004 · Cited by 1
“However, the utility of AChEIs is limited by adverse effects stemming from the nonspecific up-regulation of cholinergic signaling across the whole body [61].”
InfluentialGuin, M., Sarkar, P., Khanna, S., Arora, S., Boora, A., & Munjal, P. (2025) · Vietnam Journal of Chemistry · doi:10.1002/vjch.70059 · Cited by 1
Fereidouni, A., Nematollahi, S., Mathew, K. T., Favennec, V., Liceran, L., Aldenhoff-Kelly, C., Valdivieso, M. A., Trent, S., & Moradikor, N. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154063 · Cited by 1
Yamahashi, Y., Tsuboi, D., Funahashi, Y., & Kaibuchi, K. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2265067 · Cited by 1
Contreras, A., Jiménez‐Herrera, R., Djebari, S., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.08.593134
Hypocholinergic Stress and Neuronal Pruning in Alzheimer's DiseasePreprint
Walsh, R. (2024) · Qeios · doi:10.32388/pcber5 · Cited by 1
A Short Review on Nutritional Management of Alzheimer Disease
Barde, S. R. (2024) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2024.63797
Muscarinic acetylcholine receptors as targets for drug development
Stojković, M., Protic, D. D., & Trailović, S. M. (2025) · Medicinski podmladak · doi:10.5937/mp76-49269
Abraham, M. N., Nedeljkovic-Kurepa, A., Fernandes, T., Yaipen, O., Brewer, M. R., Leisman, D. E., Taylor, M. D., & Deutschman, C. S. (2024) · Figshare · doi:10.6084/m9.figshare.25150728
Abraham, M. N., Nedeljkovic-Kurepa, A., Fernandes, T., Yaipen, O., Brewer, M. R., Leisman, D. E., Taylor, M. D., & Deutschman, C. S. (2024) · Figshare · doi:10.6084/m9.figshare.25150570
Suo, W. Z. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0012
Computational Studies toward the Identification of CB2R-M1R Dual Modulators
Isawi, I. H., Al-Zoubi, R. M., Hajjo, R., Obeidat, R. M., AlKhawaldeh, I. H., Kilani, O. M. A., HASAN, M. K., & Morales, P. (2026) · ACS Omega · doi:10.1021/acsomega.5c07866
Synthesis of 6,7-Dihydro-5H-pyrrolo[3,4-b]pyridin-5-one Derivatives
Li, Y.-Y., Li, Z.-H., Huang, X.-Y., Ampomah‐Wireko, M., Amengor, C. D. K., Zhang, E., & Zhao, Y.-H. (2026) · Molbank · doi:10.3390/m2146
The importance of M1 muscarinic receptor phosphorylation in learning and memoryPreprint
McFall, A., Molloy, C., Gibson, K., Lindsley, C. W., & Tobin, A. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.23.713145
Self-citationWasim, M., Zia, S. R., & Ahmad, S. (2026) · Neurochemical Journal · doi:10.1134/s181971242670025x
2-Pyridone as privileged scaffold: Advances in drug design and structural modification
Shi, Y., Xu, Y., & Yu, G. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119095
Kuhn, J., Gradl, S., Osterloh, V., Gmeiner, P., Hübner, H., & Heinrich, M. R. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71318
Berida, T. I., Dodd, C. J., Wilkinson, J. C., Smith, D. R., Chang, S., Presley, C. C., Peng, L., Sant, S., Krishnan, S., Zagol-Ikapitte, I. A., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00367
Bassiouni, W., Ye, E., Colson, T. L., Ferguson, S. S. G., & Abd‐Elrahman, K. S. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104980
Maleski, A. L. A., Silva, F. A. D. C. E., Pereira, B. F., & Alberto-Silva, C. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04835-2
Badawy, A. A. ‐., Dawood, S., Clanchy, F. I. L., Williams, R. O., & Stone, T. W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156555
The influence of histamine and antihistamines on microglial regulation and neuroinflammation
Pehar, M., Westhoff, J., Fischer, D., & Kulka, M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0317
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Metadata
- Authors
- Dwomoh, L., Tejeda, G. S., & Tobin, A. B.
- Affiliations
- University of Glasgow (GB)
- Corresponding author
- Dwomoh, Louis
- Venue
- Neuronal Signaling
- Publisher
- Portland Press Ltd.
- Published
- 2022-04
- Volume
- 6
- Issue
- 1
- Pages
- NS20210004-NS20210004
- ISSN
- 2059-6553 (ISSN-L)
- PMC
- PMC9069568
- OpenAlex
- W4226325396
- Cited by
- 60
- References
- 146
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 20 · 2023: 8 · 2022: 3
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuronal Signaling (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- Alzheimer's disease, M1 muscarinic receptor, muscarinic receptor ligands, cholinergic neurotransmission, cognitive function, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.